Abstract
Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.
| Original language | English |
|---|---|
| Journal | Clinical Breast Cancer |
| DOIs | |
| Publication status | Accepted/In press - Jan 1 2018 |
Fingerprint
Keywords
- Advanced breast cancer
- Aromatase inhibitor
- Hormone therapy
- Polymorphisms
- Survival
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane : Results From a Prospective Study. / Gagno, Sara; D'Andrea, Mario Rosario; Mansutti, Mauro; Zanusso, Chiara; Puglisi, Fabio; Dreussi, Eva; Montico, Marcella; Biason, Paola; Cecchin, Erika; Iacono, Donatella; Russo, Stefania; Cinausero, Marika; Saracchini, Silvana; Gasparini, Giampietro; Sartori, Donata; Bari, Mario; Collovà, Elena; Meo, Rosa; Merkabaoui, Ghassan; Spagnoletti, Ilaria; Pellegrino, Arianna; Gianni, Lorenzo; Sandri, Paolo; Cretella, Elisabetta; Vattemi, Emanuela; Rocca, Andrea; Serra, Patrizia; Fabbri, Maria Agnese; Benedetti, Giovanni; Foghini, Laura; Medici, Michele; Basso, Umberto; Amoroso, Vito; Riccardi, Ferdinando; Baldelli, Anna Maria; Clerico, Mario; Bonura, Salvatore; Saggia, Chiara; Innocenti, Federico; Toffoli, Giuseppe.
In: Clinical Breast Cancer, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane
T2 - Results From a Prospective Study
AU - Gagno, Sara
AU - D'Andrea, Mario Rosario
AU - Mansutti, Mauro
AU - Zanusso, Chiara
AU - Puglisi, Fabio
AU - Dreussi, Eva
AU - Montico, Marcella
AU - Biason, Paola
AU - Cecchin, Erika
AU - Iacono, Donatella
AU - Russo, Stefania
AU - Cinausero, Marika
AU - Saracchini, Silvana
AU - Gasparini, Giampietro
AU - Sartori, Donata
AU - Bari, Mario
AU - Collovà, Elena
AU - Meo, Rosa
AU - Merkabaoui, Ghassan
AU - Spagnoletti, Ilaria
AU - Pellegrino, Arianna
AU - Gianni, Lorenzo
AU - Sandri, Paolo
AU - Cretella, Elisabetta
AU - Vattemi, Emanuela
AU - Rocca, Andrea
AU - Serra, Patrizia
AU - Fabbri, Maria Agnese
AU - Benedetti, Giovanni
AU - Foghini, Laura
AU - Medici, Michele
AU - Basso, Umberto
AU - Amoroso, Vito
AU - Riccardi, Ferdinando
AU - Baldelli, Anna Maria
AU - Clerico, Mario
AU - Bonura, Salvatore
AU - Saggia, Chiara
AU - Innocenti, Federico
AU - Toffoli, Giuseppe
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.
AB - Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.
KW - Advanced breast cancer
KW - Aromatase inhibitor
KW - Hormone therapy
KW - Polymorphisms
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85058825217&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058825217&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2018.11.009
DO - 10.1016/j.clbc.2018.11.009
M3 - Article
AN - SCOPUS:85058825217
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
ER -